Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
AstraZeneca
Merck
Dow
Deloitte
Medtronic
Citi
McKesson
Cipla

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,230,012

« Back to Dashboard

Which drugs does patent 7,230,012 protect, and when does it expire?

Patent 7,230,012 protects THALOMID and is included in one NDA.

This patent has twenty-six patent family members in nineteen countries.
Summary for Patent: 7,230,012
Title:Pharmaceutical compositions and dosage forms of thalidomide
Abstract:Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Inventor(s): D'Angio; Paul (Basking Ridge, NJ), McCarty; John (Miami Springs, FL)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:10/608,077
Patent Claim Types:
see list of patent claims
Dosage form;

Drugs Protected by US Patent 7,230,012

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,230,012

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,006,267 Pharmaceutical compositions and dosage forms of thalidomide ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,230,012

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I377062 ➤ Subscribe
Taiwan I359659 ➤ Subscribe
Taiwan 200731973 ➤ Subscribe
Slovenia 1562556 ➤ Subscribe
Taiwan 200505449 ➤ Subscribe
Portugal 1562556 ➤ Subscribe
New Zealand 540545 ➤ Subscribe
Mexico PA05005162 ➤ Subscribe
South Korea 20050086624 ➤ Subscribe
South Korea 100671366 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Healthtrust
QuintilesIMS
Cerilliant
Fuji
Dow
Queensland Health
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot